AstraZeneca, the Anglo-Swedish pharmaceutical company has announced plans to list its ordinary shares directly on the New York Stock Exchange.

This move is aimed at attracting a wider and more diverse base of investors.

The pharmaceutical company stated on Monday that this direct listing would replace its current American Depositary Receipts listing on the Nasdaq, streamlining its presence in the U.S. capital markets.

Despite the shift, AstraZeneca emphasized that it will maintain its headquarters, tax residency, and primary listing in the United Kingdom, and will continue to be included in Sweden’s OMX Stockholm 30 index.

The company explained that harmonizing its listing structure across global markets is designed not only to simplify its capital market presence but also to provide greater transparency and accessibility for investors worldwide.

By consolidating its U.S. listing and aligning it more closely with its primary London and Stockholm listings, AstraZeneca aims to improve liquidity, broaden its shareholder base, and facilitate more efficient trading.